Dear colleagues,
I conducted a dose-response meta analysis DR-MA (Y axis = Standardized Mean Differences from individual studies, X axis=Dose of medication).
After conducting DR-MA using cubic splines, it seems that I have a parabolic relationship. The response variable starts at 0 (since its a standardized mean difference) and as the dose medication increases, Y decreases until its vertex (turning point), then Y starts to increase after a certain dose.
I am interested in estimating the uncertainty in the turning point. I see that other colleagues have estimated the uncertainty of turning point for individual level data, but I unfortunately can't figure out how to estimate the turning point and a 95% CI using dose-response meta-analysis data. Each observation on the Y/X cartesian plane corresponds to a SMD taken from a study thus, each point on the scatter point has a weight.
I am hoping for some help solving this problem. It would be great to measure the uncertainty of turning points of meta-analyzed dose response relationships.
Thanks very much for any thoughts,
José
I conducted a dose-response meta analysis DR-MA (Y axis = Standardized Mean Differences from individual studies, X axis=Dose of medication).
After conducting DR-MA using cubic splines, it seems that I have a parabolic relationship. The response variable starts at 0 (since its a standardized mean difference) and as the dose medication increases, Y decreases until its vertex (turning point), then Y starts to increase after a certain dose.
I am interested in estimating the uncertainty in the turning point. I see that other colleagues have estimated the uncertainty of turning point for individual level data, but I unfortunately can't figure out how to estimate the turning point and a 95% CI using dose-response meta-analysis data. Each observation on the Y/X cartesian plane corresponds to a SMD taken from a study thus, each point on the scatter point has a weight.
I am hoping for some help solving this problem. It would be great to measure the uncertainty of turning points of meta-analyzed dose response relationships.
Thanks very much for any thoughts,
José
Comment